Low-dose rate telecobalt-therapy as a boost against brain-tumors.
We applied low-dose rate telecobalt therapy (LDRT) as a boost for 26 brain tumors (17 malignant gliomas, 4 pontine gliomas and 5 others). Eleven of those cases were recurrent. The LDRT; 1 Gy per hour, 7 Gy per day, a total dose of 14 Gy in two successive days, was boosted after a conventional irradiation. In malignant glioma, the local control rate and the survival rate were not improved, compared with those of the control group. The treatment results of other brain tumors were also unsatisfactory. The incidence of brain necrosis was higher in the LDRT group. The benefits of the LDRT as a boost for radioresistant brain tumors seem to be small.